Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Raw Materials (2021 - 2025)

Universe Pharmaceuticals (UPC) has disclosed Raw Materials for 5 consecutive years, with $2.5 billion as the latest value for Q3 2025.

  • Quarterly Raw Materials rose 245.78% to $2.5 billion in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.5 billion through Sep 2025, up 245.78% year-over-year, with the annual reading at $2.5 billion for FY2025, 245.78% up from the prior year.
  • Raw Materials hit $2.5 billion in Q3 2025 for Universe Pharmaceuticals, up from $720.0 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $2.5 billion in Q3 2025 to a low of $16701.0 in Q3 2022.
  • Historically, Raw Materials has averaged $642.6 million across 5 years, with a median of $2.7 million in 2021.
  • Biggest five-year swings in Raw Materials: plummeted 99.39% in 2022 and later surged 113221.79% in 2024.
  • Year by year, Raw Materials stood at $2.7 million in 2021, then tumbled by 99.39% to $16701.0 in 2022, then surged by 3704.53% to $635395.0 in 2023, then soared by 113221.79% to $720.0 million in 2024, then surged by 245.78% to $2.5 billion in 2025.
  • Business Quant data shows Raw Materials for UPC at $2.5 billion in Q3 2025, $720.0 million in Q3 2024, and $635395.0 in Q3 2023.